German-based Dynamic42, an organ-on-chip specialist, has successfully raised a mid-seven-figure financing round to support its growth and vision. The round was led by bm-t beteiligungsmanagement thüringen gmbh (bm-t), the previous lead investor, and a family office from the health sector. The funding will allow Dynamic42 to expand internationally, including a planned entry into the US pharmaceutical market. Dynamic42 offers miniaturized human organ models for drug testing that can be customized to meet individual client needs. The models can include essential components of the human immune system for investigating drug compatibility and the potential neural effects of drug candidates. The company’s technology has a high market potential as it offers better alternatives than current systems, reduces animal testing, and increases drug safety.
German company Dynamic42 secures Series A funding to expand globally with their organ-on-chip technology.
Date:
Updated: [falahcoin_post_modified_date]